MarketCap
Facebook
X
TelegramAnnual report 2022
added 12-21-2024
Genetron Holdings Limited Revenue 2011-2026 | GTH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 651 M | 532 M | 424 M | 323 M | 225 M | 101 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 651 M | 101 M | 376 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
568 M | $ 9.19 | 2.06 % | $ 612 M |  USA |
|
Biodesix
BDSX
|
71.3 M | $ 15.31 | 4.22 % | $ 1.99 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 74.11 | -2.15 % | $ 5 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 463.46 | 1.43 % | $ 13.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 159.84 | 1.16 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 165.65 | -0.81 % | $ 28.5 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.67 | 0.11 % | $ 432 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.26 | -1.46 % | $ 386 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.22 | -16.44 % | $ 6.64 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 261.71 | 1.72 % | $ 26 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 125.17 | 1.11 % | $ 19.9 B | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
15.2 M | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 7.67 | 0.72 % | $ 454 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 266.56 | 0.81 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
2.04 B | $ 59.22 | -4.09 % | $ 4.45 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 7.87 | -2.82 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
820 M | $ 193.75 | -3.17 % | $ 19.1 B | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.63 | 0.08 % | $ 277 M | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 13.82 | -0.43 % | $ 3.92 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.65 | 0.51 % | $ 941 M | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | $ 30.84 | -2.77 % | $ 1.57 B | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.14 | -1.3 % | $ 791 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 25.23 | -2.02 % | $ 701 M | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 8.05 | 7.27 % | $ 32.1 M | Israel |
 |
DexCom
DXCM
|
4.66 B | $ 66.28 | 0.51 % | $ 25.9 B | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.47 | -8.12 % | $ 96.9 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 104.91 | - | $ 19.8 B | USA |